Tarian Pharma Advances Clinical Program Toward 2026 Readouts

Tarian Pharma continues to advance its clinical pipeline with strong momentum: Our third clinical trial has been submitted to European Medicines Agency (EMA). This is TARIAN-008 for the prevention of Hand-Foot Syndrome associated with capecitabine treatment of breast and colorectal cancer. The 24-subject study is planned to initiate in early Q12026, targeting a high-need toxicity area with limited preventive options.

Tarian also has 2 other phase 2a clinical studies ongoing:

TARIAN-014 – Chemotherapy-Induced Peripheral Neuropathy (CIPN) associated with taxane treatment of breast cancer. The 30-subject trial is actively enrolling. CIPN remains a major driver of dose reductions and treatment discontinuation.

TARIAN-007 – EGFR-inhibitor–induced folliculitis (colorectal cancer): The 60-subject trial continues to progress, with 15 patients enrolled to date. EGFRi-related cutaneous reactions are among the most common and treatment-disruptive toxicities in oncology.

Topline data for all three studies are expected in Q3 2026, creating multiple near-term milestones.

Together, these programs strengthen the clinical foundation for TAR-0520, our topical gel designed to prevent and mitigate chemotherapy- and targeted-therapy–related skin toxicities which are a huge burden for cancer patients.

Indeed , 80% of cancer patients suffer cutaneous toxicities leading to:

Cancer treatment dose reductions or discontinuation in up to 30% of patients
Pain, pruritus, inflammation, sleep disruption, other
Psychological burden and significant impact on QoL

Yet, there is no approved drug for the prevention of these conditions. TAR-0520 is intended to enhance quality of life, treatment adherence, and overall patient outcomes.

With three active clinical studies, advancing regulatory interactions, and multiple readouts within the next 12 months, Tarian Pharma is entering a pivotal stage and thus offers strategic partners and potential acquirers a timely opportunity to engage with a platform addressing major unmet needs in cancer treatment.